S100 proteins are involved in biological events related to colorectal carcinogenesis. Aim of this prospective study was to assess serum concentration of S100A6, A8, A9 and A11 proteins in patients with colorectal neoplasia. Eighty-four subjects were enrolled: 20 controls (average risk population with normal findings on colonoscopy; 7 men, 13 women, age 23–74, mean 55 ± 14), 20 patients with non-advanced colorectal adenoma (non-AA, 10 men, 10 women, age 41–82, mean 62 ± 11), 22 with advanced colorectal adenoma (AA, 15 men, 7 women, age 49–80, mean 64 ± 8) and 22 with colorectal cancer (CRC, 12 men, 10 women, age 49-86, mean 69 ± 10). Peripheral venous blood was obtained. Serum S100 proteins were investigated by enzyme immunoassay technique. Serum S100A6 was significantly lower in CRC (mean 8530 ± 4743 ng/L), p = .035 compared to controls (mean 11308 ± 2968 ng/L). Serum S100A8 was significantly higher in AA (median 11955 ng/L, IQR 2681-34756 ng/L), p = .009 and in CRC (median 27532 ng/L, IQR 6794–35092 ng/L), p < .001 compared to controls (median 2513 ng/L, IQR 2111-4881 ng/L). Serum S100A9 concentrations did not differ between any tested group and controls, p > .05. Serum concentration of S100A11 was significantly lower in non-AA (mean 3.5 ± 2.4 μg/L), p = .004 and in CRC (mean 3.4 ± 2.4 μg/L), p = .002 compared to controls (mean 5.9 ± 2.5 μg/L). Sensitivity and specificity for S100A8 protein in patients with CRC were 94% and 73%; positive predictive value 68% and negative predictive value 95%. Patients with colorectal neoplasia have significantly lower serum S100A6 and S100A11 levels, significantly higher S100A8 and unaltered serum S100A9 levels.

S100蛋白参与与大肠癌发生有关的生物学事件。这项前瞻性研究的目的是评估大肠肿瘤患者血清S100A6，A8，A9和A11蛋白的浓度。共有84名受试者入选：20名对照（结肠镜检查发现的平均风险人群； 7名男性，13名女性，年龄23-74岁，平均55±14），20例非晚期结直肠腺瘤患者（非AA，10例）男性，10例女性，41-82岁，平均62±11），22例晚期结直肠腺瘤（AA，15例男性，7例女性，49-80岁，平均64±8），22例患有结直肠癌（CRC，12例男性） ，10位女性，年龄49-86岁，平均69±10）。获得外周静脉血。血清S100蛋白通过酶免疫分析技术进行研究。血清S100A6的CRC显着降低（平均值8530±4743 ng / L），p 与对照组相比= 0.035（平均值11308±2968 ng / L）。血清S100A8在AA（中位数11955 ng / L，IQR 2681-34756 ng / L），p  = .009和CRC（中位数27532 ng / L，IQR 6794–35092 ng / L）中显着更高，p  <.001与对照组相比（中位数2513 ng / L，IQR 2111-4881 ng / L）。血清S100A9浓度在任何测试组和对照组之间没有差异，p  > .05。S100A11的血清浓度在非AA（平均3.5±2.4微克/升）显著下，p  = 0.004和CRC（平均值3.4±2.4微克/升），p 与对照组相比= 0.002（平均5.9±2.5μg/ L）。CRC患者对S100A8蛋白的敏感性和特异性分别为94％和73％；阳性预测值68％，阴性预测值95％。结直肠肿瘤患者的血清S100A6和S100A11水平显着降低，S100A8血清和S100A9血清水平未改变。